Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial: Erratum

In the article “Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial,” published in the January 2020 issue of Pancreas, an error appears in the color key for Figure 2. The corrected figure appears below.

FIGURE 2.

Overall survival in NAPOLI-1 by baseline liver lesions (ITT population). Patients with baseline liver lesion data available were included in this analysis.